Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C19H16FN5O |
| Molecular Weight | 349.3616 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1=CC(NC2=NC(=NC3=C2C=CC=C3)C(O)C4=CC=C(F)C=C4)=NN1
InChI
InChIKey=DCRWIATZWHLIPN-UHFFFAOYSA-N
InChI=1S/C19H16FN5O/c1-11-10-16(25-24-11)22-18-14-4-2-3-5-15(14)21-19(23-18)17(26)12-6-8-13(20)9-7-12/h2-10,17,26H,1H3,(H2,21,22,23,24,25)
Ambit Biosciences was developing AC-430, a potent inhibitor of Janus kinase 2 (JAK2) for the treatment of cancer and autoimmune diseases. AC-430 is a racemic mixture (50/50) of two
enantiomers, AC410 and AC409. In preclinical studies, AC-430 has exhibited potency against JAK2 and V617F mutated JAK2 in cell-based models that is at least equivalent to, and in most cases superior to, competing JAK2 inhibitors. In preclinical oncology and autoimmune models, AC-430 is well tolerated and has significant efficacy at oral doses as low as 10 mg/kg/day.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB12535
Created by
admin on Mon Mar 31 20:36:02 GMT 2025 , Edited by admin on Mon Mar 31 20:36:02 GMT 2025
|
PRIMARY | |||
|
E7YVO9NSJ9
Created by
admin on Mon Mar 31 20:36:02 GMT 2025 , Edited by admin on Mon Mar 31 20:36:02 GMT 2025
|
PRIMARY | |||
|
1241914-87-3
Created by
admin on Mon Mar 31 20:36:02 GMT 2025 , Edited by admin on Mon Mar 31 20:36:02 GMT 2025
|
PRIMARY | |||
|
CHEMBL3545241
Created by
admin on Mon Mar 31 20:36:02 GMT 2025 , Edited by admin on Mon Mar 31 20:36:02 GMT 2025
|
PRIMARY | |||
|
46892373
Created by
admin on Mon Mar 31 20:36:02 GMT 2025 , Edited by admin on Mon Mar 31 20:36:02 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
